Literature DB >> 3492531

Differences among immune complexes: association of C1q in SLE immune complexes with renal disease.

S G Greisman, P B Redecha, R P Kimberly, C L Christian.   

Abstract

Studies that made use of multiple assay systems demonstrated increased levels of immune complexes (IC) in patients with systemic lupus erythematosus (SLE), but no consistent correlations of IC concentration to patterns or activity of disease have been observed. Furthermore, consistent associations between qualitative differences in IC and disease manifestations have been elusive. IC interaction with erythrocytes and mononuclear phagocytic cells is another variable in SLE that may also mediate some of the biological effects of IC. The present report concerns studies of the composition of purified IC obtained from individuals with SLE and other rheumatic diseases; a 64,000 dalton component identified as the A-B subunit of C1q was detected in purified IC from 27 of 51 SLE patients (53%). The presence of this 64,000 dalton component was not related to either IC concentration or to the serum C1q level. However, the presence of the C1q component in isolated SLE IC did correlate with the presence of renal disease (p less than 0.02). These observations are interpreted relative to a recently described kinetic model of IC clearance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492531

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Autoantibodies against C1q: view on clinical relevance and pathogenic role.

Authors:  C E Siegert; M D Kazatchkine; A Sjöholm; R Würzner; M Loos; M R Daha
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  C3-containing serum immune complexes in patients with systemic lupus erythematosus: correlation to disease activity and comparison with other rheumatic diseases.

Authors:  C Huber; A Rüger; M Herrmann; F Krapf; J R Kalden
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

3.  Molecular mechanisms for synchronized transcription of three complement C1q subunit genes in dendritic cells and macrophages.

Authors:  Guobao Chen; Carol Shurong Tan; Boon King Teh; Jinhua Lu
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

4.  [Autoantibodies against the complement component C1q in systemic lupus erythematosus].

Authors:  U Antes; H P Heinz; K Hartung; M Loos
Journal:  Klin Wochenschr       Date:  1990-11-09

5.  C1q-bearing immune complexes induce IL-8 secretion in human umbilical vein endothelial cells (HUVEC) through protein tyrosine kinase- and mitogen-activated protein kinase-dependent mechanisms: evidence that the 126 kD phagocytic C1q receptor mediates immune complex activation of HUVEC.

Authors:  S Xiao; C Xu; J N Jarvis
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

6.  Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q.

Authors:  S Uwatoko; M Mannik
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

Review 7.  Dysregulation of T Follicular Helper Cells in Lupus.

Authors:  John D Mountz; Hui-Chen Hsu; Andre Ballesteros-Tato
Journal:  J Immunol       Date:  2019-03-15       Impact factor: 5.422

8.  T cell activation by soluble C1q-bearing immune complexes: implications for the pathogenesis of rheumatoid arthritis.

Authors:  K Jiang; Y Chen; C-S Xu; J N Jarvis
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

9.  IgG autoantibodies to C1q do not detectably influence complement activation in vivo and in vitro in systemic lupus erythematosus.

Authors:  C E Siegert; M R Daha; S Lobatto; E A van der Voort; F C Breedveld
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 10.  The Potential of Harnessing IL-2-Mediated Immunosuppression to Prevent Pathogenic B Cell Responses.

Authors:  Amber Papillion; André Ballesteros-Tato
Journal:  Front Immunol       Date:  2021-04-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.